Kidney-protective therapy is now layered. How pharmacists screen, stage by KDIGO, stagger ACE/ARB, SGLT2, GLP-1, and finerenone, and cut CV risk.
Lauren Cunningham, PharmD, BCACP, CDCES
Advertisement
Lauren Cunningham, PharmD, BCACP, CDCES, is a clinical assistant professor at UIC Retzky College of Pharmacy.
Articles by Lauren Cunningham, PharmD, BCACP, CDCES
Finerenone, SGLT2s, and GLP-1s each target a different driver of CKD—pharmacists can tie every drug to a matching lifestyle change for adherence.
Chronic kidney disease (CKD) in diabetes is often caught late. Standardized eGFR and UACR screening plus thoughtful sequencing can slow progression and cut CV risk.
Advertisement
Latest Updated Articles
Screen, Stage, Sequence: CKD Care Pharmacists Can LeadAugust 26th 2026
Overcoming Barriers to Kidney-Protective TherapyAugust 21st 2026
CKD Screening Gaps in Diabetes: What Pharmacists MissAugust 18th 2026
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
4
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
5